Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer. Arlene Siefker-Radtke, MD: Looking at the data presented, ...

Despite recent advancements in our knowledge of the pathogenic mechanisms of ulcerative colitis, there is still a considerable unmet medical need for the treatment of ulcerative colitis. Because ...

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to ...

Please provide your email address to receive an email when new articles are posted on . Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination ...

Orserdu combined with Afinitor or Verzenio shows favorable tolerability and progression-free survival in ER-positive, ...

New research led by scientists at VCU Massey Comprehensive Cancer Center suggests that a class of drugs known as MCL-1 (myeloid leukemia cell-1) inhibitors interact with a type of kinase inhibitor ...

Drs Sabari and Spira comment on the use KRAS inhibitors in both frontline and combination therapies. Joshua Sabari, MD: The KRAS inhibitors are approved in the second-line settings. Sotorasib is FDA ...

FLOT neoadjuvant therapy turns the expression patterns of cancer cells similar to those of non-cancer cells in gastric cancer patients. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...

Eutelsat Communications (Euronext Paris: ETL) today host a Strategic Update on the proposed combination with OneWeb, announced in July 2022. Eutelsat and key OneWeb shareholders signed a Memorandum of ...

PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has entered into a definitive agreement (the ...